Here, we describe the technique for the microsurgical creation of giant bifurcation aneurysms in rabbits for the evaluation of endovascular devices.
Giant aneurysms are dangerous lesions requiring endovascular treatment, with high rates of aneurysm recanalization and re-rupture. Reliable in vivo models are rare but are required for testing new endovascular devices. We demonstrate the technical aspects of the creation of giant bifurcation aneurysms in New Zealand white rabbits (2.5-5.5 kg). A 25-30 mm long venous pouch is taken from the external jugular vein, and a bifurcation between both carotid arteries is created microsurgically. The pouch is sutured in the bifurcation to mimic a giant aneurysm. This protocol summarizes our previously published standard technique for venous pouch true arterial bifurcation aneurysms and highlights its essential modification steps for giant aneurysms. Using this modified technique, we were able to create an animal model for giant aneurysms with high comparability to humans regarding the hemodynamics and coagulation systems. Furthermore, low morbidity and high aneurysm patency rates were achieved. The proposed giant aneurysm model offers an excellent possibility for testing new endovascular devices.
Endovascular embolization has become an important alternative to aneurysm clipping for the treatment of ruptured cerebral aneurysms1. The main drawback of this treatment strategy is the high rates of aneurysm recanalization with delayed aneurysm rupture2. Large and giant aneurysms have been shown to be especially prone to these complications. Therefore, new endovascular devices are constantly being developed3. Models for experimental studies are essential for testing these devices4,5.
Human cerebral aneurysms have been studied in rats, rabbits, canines, and swine6,7,8. However, rabbit models have shown the best comparability to humans regarding hemodynamics and the coagulation system9,10,11,12. In the venous pouch arterial bifurcation model in rabbits, a venous pouch is sutured into a microsurgically created true bifurcation of both common carotid arteries (CCA) to mimic an aneurysm13. However, a true bifurcation model for giant aneurysms in rabbits was not available until recently. The first results using computational fluid dynamics and biomechanical testing were published by our group in 201614.
As giant aneurysms represent challenging lesions for treatment in humans and a reliable animal model is crucial for their research, we present a condensed summary of the improved techniques for the creation of giant experimental aneurysms12,13. The advantages of using this method are (i) the minimal morbidity and high aneurysm patency rates14, high comparability to humans regarding hemodynamics and the coagulation system9,10,11,12, and cost-effectiveness compared to canine methods, (ii) the true bifurcation design for a giant aneurysm13, (iii) the good hemodynamic comparability of the created aneurysms shown by computational fluid dynamics14, and (iv) the high long-term patency rates15.
The animal studies were approved by the Institute Animal Ethics Committee of the institute at which this study was conducted. For this animal model, New Zealand white rabbits (2.5-5.5 kg) were used.
NOTE: Our standard technique for the creation of the venous pouch true arterial bifurcation aneurysms in rabbits was published in 2011, and an adaption for giant aneurysms was published in 201612,13. We summarize these techniques and highlight essential steps for the modification of giant aneurysms.
1. Preoperative phase
2. Surgical phase I
3. Surgical phase II
4. Surgical phase III
5. Postoperative phase
In 2011, we published an improved technique for the venous pouch arterial bifurcation model for the creation of aneurysms in rabbits16. The mean aneurysm length was 7.9 mm, and the mean neck width was 4.1 mm. By using interrupted suture and aggressive anticoagulation, we were able to achieve 0% mortality and patency in 14 of 16 aneurysms. This technique was then adapted for the creation of giant aneurysms, and computational fluid dynamics and biomechanical testing were performed in 201614. In this study, the anesthologic management was also changed from the use of ventilation masks to intubation due to the availability of an experienced veterinarian. This represents a critical step in our experience, as the intubation of a rabbit can be difficult and lead to high preoperative mortality rates. Furthermore, the postoperative anticoagulation with low molecular heparin was reduced from 250 IU/kg to 100 IU/kg. With this regime, we were able to achieve 0% mortality and patency in 11 of 12 aneurysms. The aneurysm lengths were 21.5-25.6 mm, with neck widths from 7.3-9.8 mm. Detailed results of this study are shown in Table 1. Furthermore, these aneurysms were used for the evaluation of endovascular devices. An image of a stent-assisted embolized giant aneurysm after aneurysm retrieval is shown in Figure 1.
Figure 1: Photo of a stent-assisted embolized giant aneurysm after aneurysm retrieval. 1 left CCA, stented parent vessels; 2 right CCA, parent vessel; + embolized aneurysm sac. Please click here to view a larger version of this figure.
Aneurysm No. | Patency | Parent artery diameter [mm] | Length [mm] | Neck width [mm] | Dome width [mm] | Aspect-ratio [-] |
2 | no | – | — | — | — | — |
1 | yes | 2.4 | 23.4 | 7.7 | 9.9 | 3 |
3 | yes | 2.2 | 25.1 | 8.7 | 10.3 | 2.9 |
4 | yes | 2.5 | 23.5 | 9.8 | 10.6 | 2.4 |
5 | yes | 2.8 | 24.8 | 8.6 | 9.8 | 2.9 |
6 | yes | 2.5 | 21.5 | 9.8 | 9.3 | 2.2 |
7 | yes | 2.2 | 24.2 | 7.9 | 10.5 | 3.1 |
8 | yes | 2.3 | 25.6 | 9.3 | 10.2 | 2.8 |
9 | yes | 2.4 | 22.1 | 7.3 | 10 | 3 |
10 | yes | 2.2 | 25.6 | 8.9 | 9.7 | 2.9 |
11 | yes | 2.3 | 23.4 | 9.7 | 11.1 | 2.4 |
Table 1: Aneurysm data generated for computational fluid dynamics and biomechanical testing. The updated and detailed results of 11 aneurysms created in 2016 are shown. This table has been modified from Sherif et al.14.
There are some critical steps to ensure the replicability of the protocol described above. The meticulous removal of the thrombogenic periadventitial tissue at the anastomosis site is essential13. One must ensure that the anastomosis is tensionless and has as few sutures as possible. For giant aneurysms, it is important to begin with the back side of the anastomosis. This gives better sight and control for the most challenging sutures as compared to previously proposed procedures17,18,19.
Contrary to normal-sized aneurysms, the key factor for the retrieval of the venous pouch is the meticulous preparation of a 2-3 cm long vein segment. It is crucial to dissect all the small side branches of the external jugular vein to be able to safely ligate them. While suturing the anastomoses, direct contact with the vessels should be avoided by leaving the ends of the single sutures a bit longer. Only these free suture ends should be grabbed with the forceps to move the aneurysm complex. This technical detail helps in the use of a no-touch technique with the vessels, which is a general principle in vascular microsurgery. Another challenge, as compared to normal-sized aneurysms, is the impaired sight to the back side of the vessel aneurysm complex caused by the giant aneurysm sac. This can lead to increased technical difficulties at the rear side of the anastomosis. After completing the anastomosis, a longer flushing time is necessary due to the higher thrombus formation probability within the giant aneurysm sac. One should be aware of leakages, as they are very common. If they are not sealed with the fat pad, additional sutures should be performed.
A limitation is the use of an extracranial aneurysm as a model for intracranial pathology. Furthermore, high microsurgical requirements and well-equipped laboratories are needed for the successful implementation of this protocol. Also, rabbits are sensitive animals, and good animal housing is crucial for survival rates.
The presented model offers several advantages over the current widely used models. The most widespread current model for cerebral aneurysms is the elastase model. However, for this model, biomechanical testing of the aneurysm wall properties has never been performed. Therefore, the biomechanical comparability of this model to human conditions is unclear. On the contrary, this biomechanical testing is available for our proposed model, showing good comparability to human conditions14. Another significant advantage of this proposed model over the elastase model is the true bifurcational hemodynamics18. This model is created in a true artificially created bifurcation, while the elastase-digested aneurysm sac is formed at the dead end of the CCA, more or less mimicking a sidewall geometry.
Up to this date, there were nearly no other giant aneurysm models available. However, these models are strongly needed for the evaluation of new endovascular devices. Going through the literature, only one canine model for giant bifurcation aneurysms has been described20. However, canine hemodynamics and the coagulation system showed significant differences in comparison to humans, whereas the rabbit model has shown its superiority regarding its comparability to humans14.
Newly developed endovascular devices for aneurysm treatment are commonly tested in rabbit models. Our previously published venous pouch bifurcation aneurysms model has been used for the CE and FDA approval of such devices3,18. However, a reliable and comparable animal model for giant aneurysms in rabbits was not available until recently. In humans, giant aneurysms have the highest rates of recanalization and delayed rupture after endovascular treatment. Therefore, new endovascular devices are urgently wanted, and the industry has brought up the need for a giant aneurysm rabbit model. Another application is the evaluation of the aneurysm wall using high-field magnetic resonance imaging, which aims to identify potential risk factors for rupture, such as aneurysm wall diameter or contrast enhancement behavior22. Furthermore, long-term studies are needed to evaluate the patency of this aneurysm model over time, as well as studies showing the aneurysm behavior with flow diverter stents and intrasaccular flow diverters.
The authors have nothing to disclose.
We are grateful to Professor Heber Ferraz Leite, the Director of so many international microsurgical workshops around the world, for his open-minded and valuable teaching culture.
We acknowledge support from the Open Access Publishing Fund of Karl Landsteiner University of Health Sciences, Krems, Austria. This study was funded by a grant from the Scientific Fund of the Mayor of Vienna. The cost of this publication was funded by the Open Access Publishing Fund of Karl Landsteiner University of Health Sciences, Krems, Austria. The funding bodies played no role in the design of the study, the collection, analysis, and interpretation of the data, and the writing of the manuscript.
0.9% Saline | Any genericon | ||
4% Papaverin HCl | Any genericon | ||
Ethilon 10-0 monofil non resorbable sutures | Ethicon Inc | 2814 | Taper point needle |
Evicel Bioglue | Ethicon Biosurgery Inc. | 3901 | |
Fentanyl dermal patch 12.5 μg/h | Any genericon | ||
Heparin | Any genericon | ||
Ketamin 50 mg/mL | Any genericon | ||
Neomycin sulfate 5 mg/mL | Any genericon | ||
Vicryl 4-0 polyfilament restorable sutures | Ethicon Inc | J386H | |
Xylazine 20 mg/mL | Any genericon |